Metabolic launches Phase IIb trial
Thursday, 06 November, 2003
Melbourne-based Metabolic Pharmaceuticals (ASX:MBP) has commenced what it says is the largest clinical trial ever undertaken by an Australian biotech, a Phase IIb trial of its obesity drug, AOD9604.
The trial, with 300 "obese but otherwise health" participants, is being held at five sites in Adelaide, Melbourne, Sydney and Brisbane, the company said. It said it had amassed a large database of would-be trial participants after an item about the trial was screened on Channel Nine's A Current Affair program.
The three-month trial aims to evaluate the extent of weight loss achieved with the drug compared to a placebo. Participants will be subjected to daily oral dosing throughout the trial. Other parameters to be measured will include fat mass, blood cholesterol, glucose metabolism and perceived quality of life.
Cannabis use may double risk of cardiovascular disease death
Cannabis users have a 29% higher risk of acute coronary syndrome, a 20% higher risk of stroke,...
Space conditions can lead to periodontitis, scientists say
Living in zero gravity can lead to periodontitis — a serious condition where the gums...
Personalised brain stimulation helps treat those with depression
By tailoring transcranial magnetic stimulation to each person's unique brain structure,...
